stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+4 more quarters Free account |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (3.24) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.67 | |
EV/Operating CF |
— | — | — | 0.57 | |
EV/FCF |
— | — | — | 0.57 | |
Quick Ratio |
11.48 | 19.94 | 8.33 | 7.30 | |
Current Ratio |
11.68 | 20.36 | 8.57 | 7.87 | |
Net Debt/EBITDA |
5.71 | 8.65 | 5.07 | 6.16 | |
Debt/Assets |
0.14% | 0.16% | 0.08% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.63 | 1.27 | 0.59 | 0.77 | |
Capex/Depreciation |
0.90 | 0.19 | (0.32) | (0.13) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 196.39% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 36.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 5.60% | |
Graham Net Nets |
— | — | — | (5.94) | |
Graham Number |
— | — | — | 313.37 | |
Earnings Yield |
— | — | — | (182.01%) | |
Free Cash Flow Yield |
— | — | — | (250.37%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 6.47 | |
Operating CF per Share |
(0.56) | (0.82) | (2.72) | (6.24) | |
Capex per Share |
(0.01) | 0.00 | (0.02) | (0.08) | |
Free Cash Flow per Share |
(0.57) | (0.82) | (2.74) | (6.32) | |
Cash per Share |
5.56 | 6.28 | 24.31 | 49.23 | |
Shareholders Equity per Share |
7.68 | 9.05 | 33.50 | (118.54) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.68 | 9.05 | 33.50 | (118.54) | |
Free Cash Flow |
(20.50) | (27.59) | (16.80) | (9.77) | |
Working Capital |
186.76 | 205.25 | 135.57 | 71.53 | |
Capital Expenditures |
(0.18) | (0.08) | (0.10) | (0.13) | |
Net Current Asset Value |
179.89 | 197.96 | 134.10 | (185.74) | |
EV/EBIT |
— | — | — | 0.66 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
6.65 | — | — | — | |
Average Assets |
150.97 | 161.23 | 112.47 | 42.27 | |
Average Common Equity |
66.67 | — | — | — |
Columns are period end dates · fundamentals updated 25 Oct 2026